The possible role of the most abundant structural protein of Rift Valley fever virus (RVFV), the nucleocapsid protein (NP), in inducing protective immune responses has only been evaluated preliminarily in mice but not in any natural host species. In this study we demonstrate that a soluble recombinant RVFV subunit NP in combination with adjuvants (ISA50, Alhydrogel, TiterMax Gold or SaponinQ) is highly immunogenic in mice and sheep but the level of clinical protection and virus replication in mice after lethal challenge was dependent on the adjuvant used. Immunization with NP in combination with Alhydrogel conferred 100% protection against morbidity, mortality and viral replication in mice, but sterilizing immunity could not be achieved in sheep with any NP/adjuvant combinations used. Although this is the first study showing that sterilizing immunity can be elicited in mice immunized with a RVFV subunit nucleocapsid protein, our findings seem to suggest that mice might not be the best animal model for studying the protective ability of RVF subunit vaccines. The results of our study also emphasize the importance of adjuvant selection when evaluating subunit RVF vaccines.
INTRODUCTION
Rift Valley fever (RVF) is an emerging mosquito-borne zoonosis with severe health and socio-economic impacts [1, 2] caused by RVF virus (RVFV), a member of the Phlebovirus genus in the Bunyaviridae family [3] . Competent RVFV mosquito vectors are widespread outside the virus' current geographic range causing fears that it might spread to previously RVFV naïve regions [4] [5] [6] [7] . The RVFV genome comprises three segments (large, medium, and small) of singlestranded RNA, and is in the negative-sense, except for the small (S) segment which consists of ambisense RNA. The latter codes for the nucleocapsid (N) protein and a nonstructural protein (NSs) [8, 9] . The N protein is highly conserved and the most immunodominant viral protein in the Bunyaviridae family [10] [11] [12] [13] inducing rapid production of high levels of anti-NP humoral antibodies in infected animals and humans [14, 15] .
Vaccination of livestock in RVF endemic areas would be the most practical way of preventing the disease in animals and its spread to humans. The modified live Smithburn strain was shown to induce lifelong protective immunity but its use *Address correspondence to this author at the Pathogens Unit, National Institute for Communicable Diseases of the National Health Laboratory Service, Private Bag X4, Sandringham, 2131, South Africa; Tel: +27 11 386 6382; Fax: +27 11 882 3741; E-mail: januszp@nicd.ac.za, paweska.janusz@gmail.com is limited due to abortogenic and teratogenic properties in pregnant ewes, inadequate immunogenicity in cattle, and potential safety problems related to risks of incomplete inactivation, and reversion to virulence. The formalin-inactivated vaccines do not induce durable immunity thus necessitating annual booster vaccinations [16] [17] [18] of which administration during long inter-epizootic periods, but also due to unpredictable occurrence of RVF outbreaks, might be difficult to implement. Recent advances include development of attenuated recombinant RVFV strains by reverse genetics [19] , RVF virus-like particles [20, 21] , virus-vectors expressing RVFV genes [22] [23] [24] [25] , DNA plasmid vaccines [26, 27] and recombinant subunit immunogens [22, 24, 28] . Recombinant RVF viruses with deletions in the non-structural genes of the small (S) and medium (M) segments were highly attenuated and conferred complete protection against lethal challenge in the rat model [19] . Modified RVFV strains, however, carry the risk of being spread by mosquitoes and the possibility of recombination and reversion to virulence. Immunization of mice with RVF virus-like particles (VLP) resulted in virusneutralizing antibody responses and protection from subsequent lethal RVFV-challenge [20] . Gene gun vaccination with DNA plasmids expressing RVFV glycoproteins induced full [27] or partial protection [26] , whereas vaccination with a DNA plasmid expressing the nucleocapsid protein gave only partial protection. A recombinant vaccinia virus containing glycoprotein genes [22] , a recombinant lumpy skin disease virus vector expressing RVFV glycoproteins [24, 25] and a Sindbis virus replicon vector expressing Gn, Gc and NSm proteins [23] induced protection against RVFV challenge in mice, or mice and sheep. The use of other viruses as vaccine-vectors in regions where the wild-type viruses are endemic, however, might be problematic because of possible background immunity. Bacterially expressed recombinant subunit glycoproteins [22, 24, 28] were shown to induce varying levels of protection against RVFV challenge.
Recombinant protein subunits are generally weak immunogens [29, 30] and require administration with adjuvants to enhance their immunogenicity [31] . Adjuvants promote the uptake of antigens by antigen presenting cells (APC), contribute to the delivery of antigen to lymph nodes, and stimulate cytokine release or expression of co-stimulatory signals on APC which are needed to prime T helper cells for B cell proliferation and induction of cytotoxic T lymphocytes [29, 32] . Some of the more commonly tested and/or used adjuvants are saponins, alum and water-in-oil adjuvants. Saponin adjuvant, a surface active agent isolated from the Chilean Soap bark tree (Quillaja saponaria), modulates humoral (Th-2) as well as cellular immunity (Th-1) and bias immune responses towards the Th-1 phenotype and can induce strong CD8+ cytotoxic T-cell responses [29, 33, 34] . CD8 + T cells are able to kill virus-infected cells by inducing apoptosis, and kill infected cells directly in the lymph nodes draining infected sites [35] . Aluminium hydroxide gel (Alhydrogel), commonly known as alum allows for a depot effect at the inoculation site [29] , and has also been found to promote the release of IL-4 which results in the increased expression of major histocompatibility class II (MHC II) molecules on monocytes, consequently increasing antigen uptake by APC [36, 37] . Alum does not induce the cytokines interleukin-2 (IL-2) and interferon-gamma (IFN-) which are involved in the Th-1 type response, but might directly activate nuclear factor kappa-beta (NF-B), that is involved in regulating the cellular response to infections [37] . The NF-B is required for positive selection of memory CD8 + T cells [38, 39] . Montanide ISA50 adjuvant is based on a mannide oleate in mineral oil solution, and contributes to the establishment of a depot effect, transportation of emulsified antigen to distant sites through the lymphatic system, and interaction with mononuclear cells such as APC. ISA50 has been shown to direct the immune response against specific antigens towards the Th-2 type response, involved in humoral immunity [29] . TiterMax Gold (TMG) is a water-in-oil adjuvant that contains a metabolizable oil (squalene), sorbitan monooleate and an immunostimulatory copolymer. It has been shown to induce mixed Th-1/Th-2 responses against specific antigens, but these responses were more directed towards Th-2, indicating humoral immunity [33] . The different mechanisms by which adjuvants enhance different types of immune responses stress the importance of adjuvant selection for vaccine formulations.
In a recent study, a bacterially expressed RVFV recombinant nucleocapsid protein, together with Quil-A adjuvant, was used to immunize BALB/c mice which were subsequently challenged with a lethal dose of RVFV. A protection rate of 60% was achieved but replication of virus, or lack thereof, was not evaluated in surviving or dead mice [24] . Immunization of animals with recombinant subunit N proteins from related viruses in the Bunyaviridae family, Dobrova and Hantaan did, however, result in complete protection against viral challenge [40] [41] [42] . Recently we expressed a recombinant RVFV nucleocapsid protein, using a bacterial system, in a completely soluble form which was subsequently shown to efficiently bind antibodies from various species [15, [43] [44] [45] [46] .
In this study we expanded the earlier observations [24] by using a soluble RVFV recNP [15] together with four adjuvants to immunize mice, evaluation of its ability to induce protective immune responses not only by measuring survival ratios but also reduction of viral replication in mouse organs. Further we evaluated the immunogenicity of the recNP antigen, combined with the same adjuvants, in a host animal model and the ability of anti-recNP responses to limit viral replication in sheep after RVFV challenge. To our knowledge this is the first study showing the immunogenicity of a recombinant subunit RVFV NP in a host animal model.
MATERIALS AND METHODOLOGY

Cells and Virus
Vero cells were cultivated in Eagles Minimal Essential Medium (EMEM) (BioWhitaker, MD, USA) containing LGlutamine, non-essential amino acids, antibiotics (100 IU penicillin, 100 g streptomycin and 0.25 g amphotericin B) and 10% foetal bovine serum (Gibco) and maintained at 37ºC in 5% CO 2 incubator. The SPU22/118 KEN 07 strain of RVFV was isolated from a RVF human case during the 2007 Kenyan epidemic [47] . Second passage of the virus, propagated in Vero cells, was used for the challenge.
Bacterial Expression of Recombinant RVFV N Protein
Bacterial expression and purification of the recombinant N protein was carried out as described previously [15] . Briefly, the N gene was cloned into the pET32(a)+ expression vector (Novagen, Germany) from RNA of the RVFV Zim688/78 strain, and subsequently expressed in Origami(DE3) cells (Novagen) after induction with isopropyl -D-1-thiogalactopyranoside (IPTG, Roche, Germany) for 4 h at 37ºC. Cells were lysed with Bugbuster reagent and Lysonase (Novagen), and recombinant fusion protein containing a 6xHis tag subsequently purified from the soluble fraction using Protino Ni-chelate columns (Machery-Nagel). E. coli background proteins were not detectable in the purified end product [results shown in 15].
Mouse Immunization
Four-week old female BALB/c inbred mice were used. The low dose vaccination group (M-I) consisted of 48 mice divided in 4 sub-groups of 12 mice each which were immunized with a 100 l inoculum containing 35 g RVFV recNP in combination with ISA-50 adjuvant (Seppic, France), TiterMax-Gold adjuvant (TMG)(Sigma, U.S.A.), Alhydrogel (Sigma) or SaponinQ (60 g, Sigma), respectively. The high dose vaccination group (M-II) consisted of 48 mice which were subdivided as the M-I group but immunized with 200 l of inoculum containing 70 g of recNP in combination with the adjuvants as described above. The neat recNP group (M-N) consisted of 12 mice immunized with 70 g recNP in PBS buffer. The adjuvant control group consisted of 36 mice di-vided in 3 sub-groups of 12 mice each which were respectively inoculated only with ISA-50, Alhydrogel or SaponinQ. Note: because of immunization error a fourth adjuvant control subgroup (TiterMax Gold) was excluded from the study. The placebo control group consisted of 12 mice which were inoculated with PBS buffer. All mice were inoculated subcutaneously (s.c) using 1 ml syringes and 25 gauge needles to mimic the natural route of RVFV infection. All animals received identical booster immunizations at 14 days after the initial immunization. A mouse from each group was sacrificed and heart-bled every seven days after primary and booster immunizations to monitor immune responses. Adjuvants ISA50, TMG and Alhydrogel were used as suggested by the manufacturers. The dose of SaponinQ adjuvant (Sigma, U.S.A.) was determined by titration in BALB/c mice and by selecting the highest non-toxic dose at 60 g (results not shown). The selection of recNP doses were determined by recNP concentration and feasible mouse inoculum sizes.
Sheep Immunization
Sheep were pre-screened for antibodies against RVFV using enzyme linked immunosorbent assay (ELISA). Twenty three adult female Dorper cross sheep, younger than one year, were used. The sheep were divided into groups as described in Table 1 . All sheep were inoculated subcutaneously (s.c.) using 1 ml syringes and 25 gauge needles to mimic the natural route of RVFV infection. All animals received identical booster inoculations as described in Table 1 . Serum was collected at regular intervals, as indicated in Table 1 , for immune response monitoring.
IMMUNE RESPONSE MONITORING AFTER IM-MUNIZATION
Indirect IgG ELISA
The indirect ELISA was done as described previously [15] . Briefly, immunoplates (Maxisorb, Nunc, Denmark)
were coated with RVFV recNP antigen at a dilution of 1:2000 (0.5 g/ml) in Carbonate-Bicarbonate buffer (pH 9.6) and incubated overnight at 4ºC. After washing three times with a washing buffer consisting of phosphate buffered saline (PBS) pH7.2 and 0.1% Tween-20, the plates were blocked with 200 l of 10% fat free milk powder ("Elite", Clover SA, Pty, Ltd.) in PBS at 37ºC for 1h and then washed as before. Test sera were diluted 1:400 in diluent buffer consisting of 2% fat free milk powder in PBS, 100 l added to each well and incubated for 1h at 37ºC. Samples were tested in duplicate. After washing as before, 100 l of goat antimouse IgG horseradish peroxidase (HRPO)(H+L) at 1:2000 dilution (for mice) or recombinant Protein G HRPO (Zymed Laboratories, Invitrogen, U.S.A.) at 1:6000 dilution (for sheep) was added to the plates. After 1h incubation at 37ºC plates were washed as before and 100 l of 2,2'-azinodiethylbenzthiazoline sulfonic acid (ABTS) (KPL Laboratories, Inc., USA) added to each well. After 30 min incubation in the dark the reaction was stopped by the addition of 100 l of 1% sodium dodecyl sulfate (SDS) to each well. Optical density (OD) was determined at 405nm and the results expressed as the mean OD value for the duplicates tested. The positive control serum was generated as described previously [48] by infecting eight sheep with the AR 20368 RVFV strain and pooling highly reactive sera from collections made between day 1 and 72 post-infection. The negative control serum was serum pooled from six animals shown to be negative in the virus neutralization test as described previously [48] .
Virus Neutralization Test
In addition, a virus neutralization test (VNT) was performed on sera collected from mice and sheep after immunization to measure neutralizing ability of these sera. The VNT was performed as described previously [48] by titrating sera from a 1:10 dilution in two-fold dilutions. The titer is expressed as the reciprocal of the serum dilution that inhibited 75% of the viral cytopathic effect (CPE). 
RVFV CHALLENGE Mice
After the immunization period, 5 to 7 animals from each group were challenged with RVFV on day 32 after the booster immunization. Mice were inoculated s.c. with a 100 l inoculum containing 10 7.0 TCID 50 /ml RVF challenge virus, and after challenge examined twice daily for signs of clinical illness including loss of appetite and consequent weight loss, scruffy coat, decreased alertness, decreased mobility, loss of balance, shallow and irregular breathing, and hunched posture. Animals displaying severe illness were euthanized and organs collected. Organs were also collected at regular intervals from healthy, sick and dead mice to monitor viremia. Surviving mice were monitored for 22 days post infection. A control group was mock inoculated with Eagle's minimum essential medium (EMEM) free of the virus.
Sheep
All sheep were challenged s.c. with 2 ml challenge virus (1 ml on both sides of the neck). Sheep were challenged at different times as follows: one sheep from each sub-group (group 1a,b -4a,b), all sheep from group five and one sheep from group six were challenged on day 37 after the booster immunization (total = 13 sheep); the remaining sheep were challenged on day 168 after the booster immunization (total = 10 sheep). Sheep were monitored daily for the first two weeks after challenge and blood taken daily for the first seven days, and at regular intervals thereafter to monitor viremia and immune responses until day 70.
IMMUNE RESPONSE MONITORING AFTER RVFV CHALLENGE
Immune responses in sheep after challenge were monitored by IgM capture ELISAs as described previously [48] . A virus neutralization test (VNT) was performed as described above. Means and standard deviations for IgM ELISA readings and VNT titres were based on data from minimum two animals per group.
PASSIVE IMMUNIZATION OF MICE WITH ANTI-RECNP IMMUNE SERA
The ability of anti-N antibodies to passively confer immunity in mice was evaluated using polyclonal antisera generated in sheep, rabbits and mice. Mice were immunized with recNP as described earlier, and antisera from different recNP/adjuvant experimental groups were respectively pooled before testing. Polyclonal anti-N antisera in rabbits and sheep were produced as described previously [43] . All polyclonal sera were mixed to final dilution of 1:10 with Vero-derived virus preparation containing 10 7.0 TCID 50 /ml of the 2007 Kenya RVFV isolate, and the mixture incubated at 37ºC for 30 min before inoculation. As controls, sera from naïve sheep, rabbits and mice were mixed identically with RVFV. To control the effects of non-related compounds in serum, sterile PBS was mixed to a 1:10 with the virus. A total of 42 BALB/c 3-4 weeks old female mice, were divided into groups of 6 animals each and inoculated s.c. with 200 l of the following mixtures: a) virus and mouse anti-recNP, b) virus and sheep anti-recNP, c) virus and rabbit anti-recNP, d) virus and naive mouse serum, e) virus and naïve sheep serum, f) virus and naïve rabbit serum, and g) virus and PBS. Mice were examined twice daily clinically and those displaying severe signs of illness were euthanized. Surviving mice were monitored for 22 days post infection.
VIRUS TITRATIONS
Mouse liver and kidney tissues were homogenized as 10% (w/v) suspensions in EMEM containing L-Glutamine, non-essential amino acids, antibiotics (100 IU penicillin, 100 g streptomycin and 0.25 g amphotericin B). After centrifugation at 3000 x g, 4°C for 15 minutes, supernatants were collected and stored at -70ºC until tested.
Virus titrations of mouse tissue homogenates and sheep sera collected after challenge were performed as described previously [49] . Briefly, four 100 l replicates of 10-fold dilutions (10 -1 to 10 -8 ) of homogenates or sera were transferred into flat bottomed 96-well cell culture microplates (Nunc) and equal volumes of Vero cell suspension in EMEM containing 2 x 10 5 cells/ml, 8% FBS and antibiotics were added. The plates were incubated at 37ºC in CO 2 and observed microscopically for cytopathic effects (CPE) for 10 days post inoculation. Virus titers, calculated by the Kärber method [50] were expressed as median tissue culture infectious dose (TCID 50 ) per ml of serum or gram of tissue. Means and standard deviations from the means were determined based on two or more animals per group.
REAL TIME REVERSE TRANSCRIPTASE PCR (QRT-PCR)
Real time PCR was performed only on mouse tissue homogenates that yielded negative results by virus titration. Viral RNA was extracted from 140 l of tissue homogenates using the QIAmp ® Viral RNA Kit (QIAgen, Germany) according to the instructions of the manufacturer. The qRT-PCR was performed as described previously [49] . Briefly, amplifications were carried out in 20 l reaction mixtures containing 5 l of the extracted vRNA using the LightCycler RNA Amplification Hybprobe kit (Roche, Germany) and the Roche LightCycler instrument. Primers and a labeled probe targeting the G2 glycoprotein gene of RVFV were used.
STATISTICAL METHODS
Survival proportions in immunized mice versus control mice after challenge were compared using the Fisher exact test (Soper online statistics calculator) [51] . Viral load results in mouse organs are based on TCID 50 titrations of virus in tissues from three or more animals and given as means. P-values lower than 0.01 were considered to be significant.
The significance of differences between immune responses and viremia in sheep was confirmed using the Fisher F-test giving a two-tailed probability value (Excel, Microsoft Office). P-values lower than 0.01 were considered to be significant. Mean values and standard deviations from the means were calculated using at least two sheep per group.
RESULTS
Immunogenicity of the recNP
All recNP/adjuvant combinations induced detectable anti-recNP IgG responses by day seven after a single immu-nization of mice ( Fig. 1) with similarly increasing levels over time. The recNP without adjuvant induced a weaker but still detectable IgG response. None of the control mice (PBS or adjuvant controls) developed any antibodies against the recNP. Anti-recNP immune sera from mice were not able to neutralize the virus in-vitro (results not shown).
All sheep immunized with recNP combined with adjuvants produced detectable anti-NP IgG responses by day 14 after the first immunization (Fig. 2) . The anti-NP antibody levels of immunized sheep were consistently equal to or higher than that in experimentally infected sheep (dotted vertical line in Fig. 2) . The second immunization of all sheep 
PROTECTION OF MICE AGAINST RVFV CHAL-LENGE
All mice in the adjuvant and PBS placebo control groups died or developed severe symptoms by day six postinfection. In contrast, clinical signs in all unprotected immunized animals were delayed by four to nine days as compared to controls ( Table 2) . Clinical signs in sick animals included loss of appetite and consequent weight loss, scruffy coat, decreased alertness, decreased mobility, loss of balance, shallow and irregular breathing, and hunched posture. Only immunization with 35 and 70 g recNP/Alhydrogel, and 70 g recNP/SaponinQ yielded significant protection from disease/death (p 0.01, Fischer exact test) ( Table 2) . The best protection (100%) was achieved after immunization with both doses of recNP combined with Alhydrogel, as well as immunization with 70 g recNP/SaponinQ. The mock inoculated mice (with EMEM free of virus) did not develop any clinical signs during the experiment. Despite full or partial clinical protection resulting from immunization, the challenge virus replicated in most immunized mice, but to lower levels than in adjuvant and PBS control mice. Replication of virus could not be shown in liver and kidney tissues from mice immunized with 70 g recNP/Alhydrogel, either by virus isolation or qRT-PCR. Table 3 summarizes viral load data in mice during the acute period of infection (day 1 -6).
PASSIVE IMMUNITY BY ANTI-RECNP IMMUNE SERA
Anti-recNP immune sera did not neutralize virus in-vivo. No significant decrease in mortality/morbidity could be shown in any of the groups: a\ virus and mouse anti-recNP (survival 1/6, 17%, Fischer's exact test p = 0.500), b\ virus and sheep anti-recNP (survival 2/6, 33%, p = 0.227), c\ virus and rabbit anti-recNP (survival 0/6, 0%, p = 1.000), d\ virus and naive mouse serum (survival 0/6, 0%), e\ virus and naïve sheep serum (survival 0/6, 0%) f\ virus and naïve rabbit serum (survival 0/6, 0%), and g\ virus and PBS (survival 0/6, 0%).
IMMUNE RESPONSES IN SHEEP AFTER RVFV CHALLENGE
Because the dose of recNP did not have a significant impact on the strength of the humoral responses, groups that were immunized with the same recNP/adjuvant combination, regardless of dose, were grouped together for the RVFV challenge experiment. All adjuvant control sheep were regarded as one group, and all PBS control sheep were regarded as one group, regardless of when they were challenged with RVFV.
The sheep IgM responses after challenge are shown in Fig. (3A) and in Fig. (3B) . None of the immunized or control sheep had any detectable RVFV specific IgM antibodies on the days they were challenged. High levels of RVFV specific IgG, however, was detected in all immunized sheep on the days they were challenged, but as expected not in control The virus neutralizing antibody responses after challenge are shown in Fig. (4A, 4B) . Immunization did not have significant effect on decreasing the development of virus neutralizing antibodies when compared to PBS control sheep: recNP/ISA50 (day 37, p = 0.883; day 168, p = 0.825 Fisher F-test), recNP/Alhydrogel (day 37, p = 0.920; day 168, p = 0.850), recNP/TiterMax Gold (day 37, p = 0.881; day 168, p = 0.975) and recNP/SaponinQ (day 37, p = 0.682; day 168, p = 0.858).
VIREMIA IN SHEEP AFTER RVFV CHALLENGE
The viremia in sheep after RVFV challenge is shown in Table 4 . Immunization of sheep did not result in significant decrease of viral loads in sera when compared to PBS control sheep. Viremia was, however, of two to four days duration whereas one PBS control sheep developed pro- 
DISCUSSION
There is no available RVF vaccine for humans and the currently in use live-attenuated and inactivated animal vaccines are expensive to produce and pose safety problems. Recombinant DNA technology has proven to be a useful tool for the development of alternative vaccine candidates for RVF, including recombinant subunit vaccines, recombinant attenuated virus prepared by reverse genetics, virus like particles and recombinant viruses using a non-related virus as backbone for RVF antigens. These new generation vaccines have been shown to have their distinct advantages and disadvantages, but have mostly targeted the glycoproteins of the virus which are known to induce protective neutralizing antibodies [22, 25, 27, 28] . 
Days post infection (challenge day 168)
The nucleocapsid protein induces production of high levels of anti-NP specific IgG and IgM responses in host animals [14, 15] . It has been postulated that the strongly biased humoral antibody response to N protein might be a part of virus strategy to direct the host immune response towards viral antigenic determinants not relevant in protection [52] . On the other hand, immunization of animals with recombinant subunit N proteins from related bunyaviruses resulted in complete protection against viral challenge [40] [41] [42] . Immunization with a recombinant RVFV nucleocapsid protein with Quil-A adjuvant protected 60% of mice from lethal challenge [24] . Immunization of mice with cDNA encoding the N protein resulted in 50% protection from clinical signs after the induction of NP-specific lymphoproliferative responses [26] but the replication of challenge virus in immunized mice was not evaluated and there was 86% recovering rate in naïve mice indicating low challenge. Immunization of mice with virus like particles containing both glycoproteins and the N protein resulted in 92% protection [20] . This protection was most probably due to the presence of glycoproteins in the VLP since anti-NP responses could not be detected after immunization. Immunization of mice with VLPs containing the glycoproteins and NP resulted in better protection against lethal challenge when compared to those immunized with VLPs without NP [21] . Immunization of sheep with a DNA construct expressing the RVFV N protein resulted production of anti-NP antibodies but protection against RVFV challenge was never evaluated [52] . From these earlier reports it seems that the anti-NP response does play a role in protection of mice against morbidity and mortality from RVFV infection. The decrease of viral replication in these immunized mice have, however, not been evaluated yet.
Vaccination against arthropod borne viruses should ideally aim to decrease morbidity and mortality, but even more importantly it should stop the spread of the virus by inducing sterilizing immunity. From the previous studies it is unclear whether NP immunization was able to decrease viral replication in challenged animals. The protective ability of the anti-NP response in a host animal species, such as sheep, has never been evaluated. In this study we evaluated a recombinant subunit N protein of RVFV as an immunogen, in combination with four different adjuvants, in mice and measured its protective ability against RVFV challenge by using survival rates as well as decrease of viral replication after severe RVFV challenge. We also evaluated for the first time a recombinant subunit RVFV NP as an immunogen in a host animal model, sheep, and its ability to decrease viral replication in sheep after severe RVFV challenge. To our knowledge this is the first study evaluating the effect of anti-NP immunity on viral replication in both mice and a host animal species.
Four different adjuvants with differing mechanisms of enhancing immune responses were used in this study to evaluate whether this could have an effect on the level of protection against severe RVFV challenge. The RVFV recNP used was not only highly immunogenic in mice and sheep in combination with all adjuvants, but also induced a measurable response in the absence of adjuvant in mice. Even though in the limited number of mice tested at each time point there wasn't drastic differences in the strength of humoral responses in mice after immunization, there were significant differences in the level of protection against challenge. The best protection against morbidity and mortality (100%) was achieved with 35 or 70 g of the recNP when combined with Alhydrogel adjuvant, or 70 g recNP with SaponinQ. Additionally no virus or viral RNA could be detected in the liver or kidney tissues from mice immunized with 70 g recNP/Alhydrogel after RVFV challenge, indicating possible sterilizing immunity. Alhydrogel, more commonly known as alum, promote the release of IL-4 which results in the increased expression of MHC-II molecules on monocytes, consequently increasing antigen uptake by antigen presenting cells (APC) [36, 37] . Alum also activates NF-B, a protein complex found in almost all cell types and that is involved in regulating the cellular response to infections by effecting positive selection of memory CD8 + T cells [37] [38] [39] . This is the first study showing 100% protection from morbidity and mortality and viral replication in mice immunized with a RVFV subunit nucleocapsid protein after severe RVFV challenge, and confirms previous findings that the anti-NP response does play a role in protecting mice from RVFV challenge [20, 21, 24, 26] Other recNP/adjuvant combinations were not as effective as Alhydrogel in inducing protective and sterilizing immunity. The mice immunized with 70 g recNP/SaponinQ was also 100% protected from morbidity/mortality but replicating virus or viral RNA was found in the organ tissues of some of the mice in this group. The lower dose of the recNP/SaponinQ combination was less effective and resulted in protection of only 67% of mice from morbidity/mortality while virus still replicated in their organs. Saponins modulate humoral (Th-2) as well as cellular immunity, but seem to be more effective via the Th-1 cellular route and can induce strong CD8+ cytotoxic T-cell responses [34] . The two adjuvants that enhance immune responses by very similar mechanisms, ISA50 and TiterMax Gold, were equally ineffective in inducing significant protective and sterilizing immunity in mice after RVFV challenge. These two adjuvants induce mixed Th-1/Th-2 responses, but responses are usually biased towards Th-2 which is indicative of a stronger humoral response [29, 33, 53] . The worst protected immunized mice were those in the group immunized only with recNP and no adjuvant. Our findings emphasize the importance of an adjuvant in modulating a desired protective immune response to a specific antigen.
Irrespective of the dose used all recNP/adjuvant combinations were highly immunogenic in sheep even after a single immunization. Anti-NP IgG responses in immunized sheep were equal to or higher than the level of anti-NP antibodies in experimentally infected sheep. After RVFV challenge the control sheep developed strong IgM response, which in immunized sheep was much weaker, but still detectable after challenge. Although these results might have indicated lower virus replication in immunized sheep after challenge; surprisingly there were no significant differences in the virus neutralizing titres in immunized sheep when compared to control sheep. Also, humoral immunity against the NP was not able to significantly decrease viremia when compared to control sheep.
The results of the study demonstrate that sterilizing immunity could be induced with a recombinant subunit RVFV nucleocapsid protein in a mouse model when used with specific adjuvants, but the same recNP/adjuvant combinations were not able to induce the same level of immunity in a ruminant host species. Our findings highlight also some important aspects that should be considered for future research and development of vaccine candidates for RVF. Firstly the anti-nucleocapsid response alone, although protective in mice, does not seem to play a role in protection of an actual host species against RVFV infection. Secondly, our results show that mice might not be the best animal model for studying protective ability of RVF vaccines. Although the target proteins of choice for RVFV vaccines are glycoproteins because of inducing neutralizing antibody, RVFV vaccine candidates targeting the glycoproteins which were evaluated in mice have also yielded inconsistent protection against challenge [20, 21, 23] . In a recent study it was shown that immunization with VLPs combining the glycoproteins and nucleocapsid protein yielded better protection [21] . Therefore it appears that vaccine candidates combining glyco-and nucleocapsid proteins should be further investigated.
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